Hospira re-launches generic Eloxatin in US
Initially in 50mg and 100mg single-use vials
Hospira, a leading provider of injectable drugs and infusion technologies, has announced the US re-launch of oxaliplatin injection, a generic version of Sanofi's chemotherapy medication Eloxatin.
Hospira will initially offer the solution form of oxaliplatin injection in 50mg and 100mg single-use vials for the treatment of colon and colorectal cancer.
Sales of Eloxatin last year in the US were approximately US$1.5bn.
Hospira’s Joshua Gordon, vice president of Speciality Pharmaceuticals, said: ‘We're excited once again to be able to provide this critical oncology drug to our patients and customers.’
Hospira originally launched oxaliplatin injection in August 2009 following a favourable ruling in patent litigation with Sanofi.
Under an agreement, which eventually called for the suspension of Hospira’s sales at the end of June 2010, Hospira settled the litigation with Sanofi with the right to re-launch the product well in advance of patent expiry.
Hospira is a market leader for generic injectable pharmaceuticals. The firm’s therapeutic areas include analgesia, anaesthesia, anti-infectives, cardiovascular, oncology and other areas. Hospira’s SIP portfolio also includes several in-licensed products, such as Precedex (dexmedetomidine HCl), a proprietary sedation agent.
